Biotech Firms, Billions at Risk, Lobby States to Limit Generics - By ANDREW POLLACK NYTimes.com

Quicklink submitted By   Follow Me on Twitter     Message Susan Lee Schwartz     Permalink
Related Topic(s): ; ; ; ; ; ; ; , Add Tags

Must Read 1   News 1   Valuable 1  
View Ratings | Rate It

opednews.com

This is insidious way the corporations undo any health care legislation that benefits the people. While the media gives the people celebrity gossip and dwells on disasters and sexy news, the lobbists undo everything.

"In statehouses around the country, some of the nation's biggest biotechnology companies are lobbying intensively to limit generic competition to their blockbuster drugs, potentially cutting into the billions of dollars in savings on drug costs contemplated in the federal health care overhaul law.

"The drugs now cost patients -- or their insurers -- tens or even hundreds of thousands of dollars a year.

"Two companies, Amgen and Genentech, are proposing bills that would restrict the ability of pharmacists to substitute generic versions of biological drugs for brand name products."

Read the rest of the story HERE:

At www.nytimes.com

- Advertisement -
- Advertisement -